Dalazatide

Drug Profile

Dalazatide

Alternative Names: Debio-0824; ShK-186

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Airmid; University of California at Irvine
  • Developer Kineta; KPI Therapeutics; Seattle Childrens Research Institute; University of California at Irvine; University of Groningen
  • Class Amides; Peptides; Proteins
  • Mechanism of Action Kv1.3 potassium channel inhibitors; T lymphocyte modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Plaque psoriasis; Psoriatic arthritis
  • Preclinical Lupus nephritis; Vasculitis
  • Research Inflammatory bowel diseases; Multiple sclerosis
  • No development reported Autoimmune disorders; Obesity

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Autoimmune-disorders(In volunteers) in Netherlands (SC, Injection)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Obesity in USA (SC, Injection)
  • 09 Jun 2015 Early research in Inflammatory bowel disease and Multiple sclerosis in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top